Sort
17,288 grants matching “multiple sclerosis”
Development of a first-in-class therapeutic for producing 'on-demand' voiding
$300,000Karl B Thor · Dignify Therapeutics, Llc · R44 · FY2017 · DK
Safe and effective anti CD154 antibodies for therapeutic intervention
$300,000Susan Dana Jones · Immurx Llc · R43 · FY2012 · AI
Treating EAE disease with Fc-Dimers
$300,000David M Mosser · Leukosight, Inc. · R41 · FY2013 · AI
Small Molecule Targeting of Viral Non-Coding RNA EBER1 to Detect and Treat Latent EBV
$300,000Ursula D Ramirez · Vironika, Llc · R43 · FY2019 · AI
MOLECULAR BASIS OF THEILER'S VIRUS-INDUCED DEMYELINATION
$300,000Evanston Northwestern Healthcare · R01 · FY2002 · NS
Development of Kv1.3 channel blocker ShK-186 as a therapy for multiple sclerosis
$300,000Shawn Patrick Iadonato · Kineta, Inc. · R43 · FY2011 · AI
Treating EAE disease with Fc-Dimers
$300,000David M Mosser · Leukosight, Inc. · R41 · FY2012 · AI
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)
$300,000Stephanie J Lee · Fred Hutchinson Cancer Research Center · U54 · FY2014 · CA
Integrating microfluidic vortex shedding-mediated gene delivery into the development and manufacture pipelines of adoptive cellular immunotherapies
$300,000Justin Ansel Jarrell · Indee, Inc · R43 · FY2020 · AI
Medicinal Chemistry Based Optimization of Lead Compounds Against Multiple Scleros
$300,000Antonio J Barbosa · Adhaere Pharmaceuticals, Inc. · R43 · FY2014 · AI
Small Molecule Inhibitors of ZAP-70 for the Treatment of Autoimmune Disorders
$300,000Mark Gallop · Nurix, Inc. · R43 · FY2013 · AI
A Novel Tolerance-inducing Probiotic Platform
$300,000Neil A Fanger · Virtici, Llc · R43 · FY2017 · AI
Development of Diagnostic Test for Early Multiple Sclerosis
$299,998Steven E Schutzer · Bioscience Development, Inc. · R43 · FY2015 · NS
New Epigenetic Therapy for Multiple Sclerosis
$299,983Qiang Zhang · Parkside Scientific, Inc. · R43 · FY2019 · AI
Nanocarrier-formulated NF-kB inhibitors for Inflammatory diseases
$299,976Gerardo M. Castillo · Pharmain Corporation · R43 · FY2011 · AI
Nanocarrier-formulated NF-kB inhibitors for Inflammatory diseases
$299,973Gerardo M. Castillo · Pharmain Corporation · R43 · FY2012 · AI
CD24 Polymorphism and multiple sclerosis
$299,957Yang Liu · University Of Michigan At Ann Arbor · R01 · FY2007 · NS
Develop natural compound emodin as a novel therapy for calcific aortic valve disease
$299,953Mohamad Azhar · Acepre, Llc · R41 · FY2024 · HL
Brain-Computer Interface Control of Ambulation
$299,952Zoran Nenadic · University Of California-Irvine · · FY2012 · ENG
RENYC. Rare Epilepsies in New York City: Epidemiology and Health Outcomes. Improving Surveillance with Text Processing of Clinical Notes in Electronic Health Records.
$299,922Zachary Michael Grinspan · Weill Medical Coll Of Cornell Univ · U01 · FY2015 · DP
Pathogenesis of anti-ganglioside antibody-mediated neuropathies
$299,917Kazim A Sheikh · University Of Texas Hlth Sci Ctr Houston · R01 · FY2010 · NS
Determinants of the Cannabinoid Receptor Life Cycle
$299,880Debra A Kendall · University Of Connecticut Storrs · R01 · FY2009 · DA
Silencing autoantibody secretion for SLE therapy
$299,865Andrew R Mendelsohn · Larix Bioscience, Llc · R43 · FY2023 · AI
Role of CTL escape mutants in MHV-induced demyelination
$299,835Stanley Perlman · University Of Iowa · R01 · FY2007 · NS
Role of CTL escape mutants in MHV-induced demyelination
$299,835Stanley Perlman · University Of Iowa · R01 · FY2008 · NS